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Timely diagnosis and treatment of maternal tuberculosis (TB) is important to reduce morbidity and mortality for both the
mother and child, particularly in women who are coinfected with HIV. The World Health Organization (WHO) recommends the
integration of TB/HIV screening into antenatal services but available diagnostic tools are slow and insensitive, resulting in delays
in treatment initiation. Recently the WHO endorsed Xpert MTB/RIF, a highly sensitive, real-time PCR assay for Mycobacterium
tuberculosis that simultaneously detects rifampicin resistance directly from sputum and provides results within 100 minutes. We
propose a model for same-day TB screening and diagnosis of all pregnant women at antenatal care using Xpert MTB/RIF. Pilot
studies are urgently required to evaluate strategies for the integration of TB screening into antenatal clinics using new diagnostic
technologies.
1. Introduction
Tuberculosis (TB) is a leading cause of nonobstetric maternal
death in resource-limited settings, accounting globally for
approximately 700,000 deaths every year, the majority of
which are in areas with high HIV prevalence [1, 2]. In South
Africa, a screening study found that the prevalence of TB
is 10 times greater in HIV-infected than in HIV-uninfected
pregnant women [3] and Gouder et al. found TB prevalence
among women attending antenatal care was 696/100,000
among HIV-infected women compared to 200/100,000
among HIV-negative women [4]. If untreated, maternal
TB can lead to increased neonatal mortality, lower birth
weights, prematurity [5, 6] and increased complications
of pregnancy, including a four-fold increase in maternal
morbidity through higher rates of abortion, postpartum
hemorrhage, labor difficulties, and preeclampsia [7, 8].
Furthermore studies have demonstrated that HIV-infected
pregnant women who are coinfected with TB are 2.5 times
more likely to transmit HIV to their babies than women
without TB [9] and their infants are 24 times more likely to
have neonatal TB [10]. Under current standards in resource-
limited settings there is a significant delay from the time
of presentation to the diagnosis of TB, due to the low
sensitivity and long turnaround time of available diagnostic
tools, the need for multiple visits, and the nonspecificity of
symptoms in pregnant women, particularly those who are
HIV infected. In Mexico, Figueroa-Damian found maternal
morbidity, neonatal mortality, and extreme prematurity all
to be significantly higher among pregnant women with TB
who started treatment late in pregnancy (25–36 weeks of
gestation), whilst those treated early had minimal negative
outcomes [11, 12]. In addition, rapid, early diagnosis and
treatment of TB reduces transmission of TB to family
members, including newborns, and the wider community
[13] and reduces the number of women who are lost to
followup during the lengthy TB diagnostic process. In light of
these risks, it is clear that early, rapid diagnosis and treatment
of both HIV and TB is critical to improve both maternal
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and infant outcomes [14]. The World Health Organization
(WHO) recommends the integration of TB/HIV care into
antenatal services and TB screening of all pregnant women
in high HIV prevalence areas [15].
2. TB Diagnosis in Pregnant Women
To date the implementation of WHO antenatal TB screen-
ing recommendations has been limited in resource poor
countries due in part to significant financial and logistical
constraints [16]. Clinicians are reluctant to use chest radio-
graphy as part of the TB diagnostic workup process and
sputum smear microscopy using Ziehl-Neelsen (Z-N) stain
has been demonstrated to have low sensitivity, especially
in HIV-infected women. The WHO estimates that Z-N
microscopy detects only 58% of pulmonary TB cases in
HIV-infected individuals [17]. Sensitivities even lower than
this have been reported; in a South African study, eight
of 370HIV-infected pregnant women were diagnosed with
culture-confirmed TB but all were smear negative [18].
Despite being the diagnostic reference, standard TB culture
is not accessible in most resource-limited settings due to its
complex laboratory requirements. A potential alternative is
the recently recommended Xpert MTB/RIF, a real-time PCR
assay for Mycobacterium tuberculosis that simultaneously
detects rifampicin resistance directly from sputum and
provides results within 100 minutes [19]. Xpert MTB/RIF
has been recommended for use up to the subdistrict level,
especially in settings where rapid access to appropriate
treatment and care is required [20]. Results from prospective
demonstration studies involving 6,648 individuals found the
sensitivity of a single, direct Xpert MTB/RIF test in culture-
positive cases was 90.3% (99.0% in smear-positive sputa and
76.9% in smear-negative sputa), rifampicin resistance was
detected with 94.4% sensitivity and 98.3% specificity and
performance was not significantly affected by HIV status [21,
22]. Operationally Xpert MTB/RIF technology has shown
to be robust in various locales and can be used outside
laboratory settings by lay staff with minimal training [21].
These characteristics suggest that Xpert MTB/RIF may have
the potential to play a significant role in the diagnosis of TB
in antenatal settings in low-resource settings with generalized
HIV epidemics.
Using the example of Zambia, there are approximately
5000 women who present monthly for antenatal care at
the 25 government primary healthcare clinics in the capital,
Lusaka. In these health clinics the mean gestational age of
women at their first antenatal visit is 22 weeks and almost
half (48%) come for only one visit [23]. Over 90% of
expectant women agree to HIV testing during antenatal
care and approximately 22% are HIV infected. Despite
well-developed HIV testing programs in Maternal Child
Healthcare (MCH) departments, there is no provision for
systematic TB screening and limited data available within
Zambia to guide best practice. Currently, pregnant woman
presenting to MCH with TB symptoms are referred to the
outpatient department (where there are often long queues)
for further consultation, sputum collection, and antibiotic
trials. Often multiple visits are required over several days to
weeks prior to receiving a final diagnosis and women may be
lost to followup before the diagnostic process is complete.
While there is no data on the diagnostic delay between
initial presentation and TB diagnosis in pregnant women,
an evaluation of the 2007 WHO guidelines found that
median time to TB treatment initiation was between 3–17
days for smear-negative pulmonary TB [24] and a review
of records at one Lusaka HIV clinic found the average
time from first presentation to pulmonary TB diagnosis
to be 29 days (personal communication, S. Trollip). Due
to more complicated referral systems, this delay may be
even greater in MCH clinics The combination of insensitive
tools and lengthy diagnostic delays highlights the urgent
need to integrate TB screening into antenatal care and to
pilot faster, more sensitive diagnostic tools. Introduction
of the Xpert MTB/RIF technology, which provides same-
day TB diagnosis with high sensitivity, could potentially
allow pregnant women to be screened and started on TB
treatment the same day as their antenatal visit. Based on
current practice this would represent a reduction of up to 3
weeks in time to TB treatment initiation, critically given that
most women present late in pregnancy.
3. TB Screening Model in Antenatal Clinics
Screening pregnant women for TB inMCHmakes sense both
clinically and logistically as even in low-resource settings a
majority of women access health care during pregnancy at
least once [25]. Rather than strengthening the limited and
separate TB diagnostic services at the clinic, integration of
TB diagnostic and antenatal services would leverage existing
clinic space and staff, simplify patient flow, and reduce
waiting times.
We propose a model (Figure 1) to integrate TB and HIV
screening, diagnosis, and treatment into existing antenatal
care using Xpert MTB/RIF technology. Women present early
in the morning to the antenatal clinic and while they wait
for individual check-ups, group health education is given by
a trained lay worker/peer educator. These health education
talks provide an opportunity to deliver counseling on the
TB and HIV screening services and the clinical benefits to
both mother and child of TB (and HIV) screening during
pregnancy. In this model, lay healthcare workers administer a
simple TB symptom questionnaire that evaluates patients for
key TB symptoms (any cough, fever, night sweats, or weight
loss). Asymptomatic women are referred for provider-
initiated counseling and testing (PITC) and continue with
the standard antenatal visit where they may be considered
for isoniazid prophylaxis therapy. Symptomatic (presence
of any symptom) women are escorted to an isolated and
well-ventilated area for sputum collection and afterwards
for PITC. Utilizing Xpert MTB/RIF technology, sputum
is analyzed in the clinic laboratory or within the MCH
department, depending on space availability, security, and
stable electricity supply. The clinician provides a formal
assessment once TB and HIV test results are available.
Women with positive TB and/or HIV test results are referred
for further evaluation and, optimally, TB treatment will be
initiated the same day.
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Screened for TB with Xpert
MTB/RIF
Xpert MTB positive,
RIF resistant
Xpert MTB positive,
RIF sensitive
Xpert MTB
negative
Refer to national
MDR TB treatment
program
Women present at MCH for
antenatal care
Sensitization talk given by
Lay-workers on importance of
HIV/TB screening and treatment
Woman has no TB
symptoms
HIV PITC conducted while
women wait for Xpert
MTB/RIF result
Women sees clinician for
TB/HIV test results
Registration, triage and TB
symptom screening
questionnaire by Lay-workers
Woman has one or more TB
symptoms (any cough,
fever, night sweats or
weight loss)
Refer to TB clinic.
Refer for ART care
if HIV positive
Continue standard
antenatal care at
MCH. Refer for
ART care if HIV
positive
HIV PITC conducted
Continue standard
antenatal care at
MCH. Refer for
ART care if HIV
positive
Figure 1: Proposed model for same-day TB screening and diagnosis of pregnant women at antenatal care using Xpert MTB/RIF (∗MCH:
Maternal Child Healthcare Clinic; (M)TB: (Mycobacterium) Tuberculosis; RIF: Rifampicin; PITC: Provider Initiated Testing and Counseling;
ART: Antiretroviral therapy; MDR: Multidrug resistant).
4. Discussion
We have highlighted the need for TB screening in pregnant
women and proposed a model for a point of care screening
algorithm with rapid turnaround time. Variations of this
model may be appropriate for different settings depending
on patient flow, space, and staffing. Faster diagnosis of
TB leads to earlier cotreatment, reduced transmission to
community and family, and potentially improved maternal
and neonatal clinical outcomes. The proposed use of Xpert
MTB/RIF technology has substantial advantages in terms
of sensitivity, turnaround time, and simplicity compared
to existing technologies however implementation challenges
exist; the instrument and storage of cartridges requires
significant space, waste generated is considerably more than
that with microscopy, and instruments require an unin-
terrupted power supply and annual validation. At present,
Xpert MTB/RIF operation requires substantial expenditure,
both in capital costs and consumables. In 2011, the Founda-
tion for New Innovative Diagnostics (FIND) negotiated price
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for a 4-module unit (capable of running 16–20 specimens per
day) is 17,000USD and the price per cartridge is 16.86 USD
(with one cartridge required per sputum tested). On the long
term, prices for Xpert MTB/RIF are expected to decrease as
global testing volumes increase [20]. Further work is required
to examine its cost-effectiveness in various resource-limited
settings. In addition, Xpert MTB/RIF technology relies
on the ability of a patient to produce sputum which is
problematic for those without pulmonary symptoms. Future
pilots could also consider other less expensive nonsputum-
based diagnostic tools that are currently under evaluation,
such as a urine lateral flow test for simple and rapid lipoara-
binomannan (LAM) detection [26] or simplified nucleic
acid amplification tests like the loop-mediated isothermal
amplification (LAMP) assay [27], after their endorsement by
the WHO.
The possible clinical benefits of an integrated system
are apparent and acceptance of screening is potentially
high as pregnant women generally have increased health
seeking behavior to protect their unborn child; however it
is important to recognize potential patient-related barriers
to implementation. For example, Kali et al. found that
44% of HIV-infected pregnant women were unwilling to
go through TB screening [18]. However, TB screening was
offered after PITC, suggesting that women may have been
reluctant to face another potential diagnosis immediately
after learning that they were HIV infected and may be
unwilling to wait the additional 2 hours required to obtain an
Xpert MTB/RIF result. Women needing treatment for HIV
may be especially reluctant to engage in TB screening for fear
of the heavy pill burden associated with TB/HIV treatment,
during pregnancy. Screening all women for both diseases
on arrival, as proposed in this model, may increase uptake
and strengthen acceptance of the need for routine HIV
and TB screening in high-prevalence settings. Furthermore
strong linkages to care and comprehensive sensitization at
both clinic and community level is essential to “normalize”
TB screening in the pregnant population and overcome
reluctance to screen.
Integration of HIV and TB screening services into MCH
using similar models has been shown to be feasible and
recommended in high HIV/TB prevalence settings [14, 16].
A simple screening questionnaire that assesses patients for
any of the four key TB symptoms has been proven to
accurately identify people in need of further diagnostic
assessment in resource-constrained settings [28]. In addition
the use of lay workers to conduct a symptom screening has
been successfully piloted in South Africa where it added
only 4–7 minutes to the visit time [18]. In Zambia lay
workers/peer educators have been instrumental to the rapid
scale-up of both HIV programs (conducting testing, adher-
ence counseling, and followup of patients on treatment)
[29, 30]; TB programs (conducting PITC, sputum collection,
directly observed treatment strategy and facilitating referral
linkage). As Xpert MTB/RIF instruments are reported to
be simple enough to be run by lay workers this greatly
increases the feasibility of using them in countries that have
significant shortages of professional health care staff [21].
Despite this, implementation of a screening program, as we
have proposed, will have a significant impact on the logistics
of MCH visits; additional staff and appropriate space will be
required for optimal implementation.
There remain many unanswered questions about TB
screening in the antenatal setting that need to be addressed by
operations research. These include optimal linkage between
MCH and TB care; adherence barriers and toxicity facing
coinfected pregnant mothers in receiving TB and HIV
cotreatment; effects of early TB/ART initiation on maternal
and neonatal outcomes and neonatal HIV transmission; time
to ART and TB initiation in coinfected pregnant women;
feasibility and cost-effectiveness of Xpert MTB/RIF imple-
mentation in antenatal clinics; sensitivity and specificity
of Xpert MTB/RIF in pregnant women; the role of lay
workers/peer educators in integrated screening programs.
Pilot programs are urgently needed to evaluate the impact
of integrating TB screening strategies into antenatal clinics
using new diagnostic technologies in order to reduce the
burden of TB and HIV in mothers and their children.
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